Positive Effect of Etidronate Therapy Is Maintained After Drug Is Terminated in Patients Using Corticosteroids
Jacques P. Brown(Centre hospitalier de l'Université Laval), Jonathan D. Adachi(St. Peter's Hospital), Louis‐Georges Ste‐Marie(Centre Hospitalier de l’Université de Montréal), David L. Kendler(University of British Columbia), Brian C. Lentle(University of British Columbia), Robert G. Josse(Western University), Simon Pack(Procter & Gamble (United States)), John G. Hanly(Queen Elizabeth II Health Sciences Centre), David A. Hanley(The University of Sydney), Arkadi Chines(Procter & Gamble (United States)), George Ioannidis(McMaster University Medical Centre), Alan Tenenhouse(St. Vincent's Birmingham), Tassos Anastassiades, A. Jovaisas, Reginald Dias, I Barton(Procter & Gamble (United Kingdom)), Greg F. Stephenson(Procter & Gamble (Canada)), Wojciech P. Olszynski(University of Saskatchewan), W. Bensen(St. Joseph Hospital), Anthony B. Hodsman(Western University)
Cited by 8
Related Papers
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Body mass index as a predictor of fracture risk: A meta-analysis
|Osteoporosis International|2005|1.6k
Predictive Value of BMD for Hip and Other Fractures
|Journal of Bone and Mineral Research|2005|1.5k
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
|New England Journal of Medicine|2014|1.2k